November 05, 2026

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Subject : ***Outcome of Board Meeting-November 05, 2026***

Stock Code : ***BSE – 539787, NSE – HCG***

Reference : ***Regulation 30, 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations")***

Further to our intimation dated October 13, 2026, and pursuant to Regulation 30, 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company at its meeting held on November 05, 2026, has, *inter alia*, considered and approved the Unaudited Financial Results of the Company (Standalone and Consolidated), for the quarter and six months ended September 30, 2026 ("Unaudited Financial Results").

In this regard, please find enclosed herewith the Unaudited Financial Results. The financial results are also being made available on the website of the Company and can be accessed at: https://www.hcgoncology.com/.

The meeting of the Board of Directors commenced at 11.15 a.m. and concluded at 07.45 p.m.

Kindly take the intimation on record and acknowledge receipt of the same.

Thanking you,

For **HealthCare Global Enterprises Limited**
SUNU MANUEL ABEY
Digitally signed by SUNU MANUEL ABEY
Date: 2026.11.05 20:03:51 +05'30'
Sunu Manuel
Company Secretary & Compliance Officer

Encl: a/a.

B S R & Co. LLP
Chartered Accountants

Embassy Golf Links Business Park
Pebble Beach, B Block, 3rd Floor
No. 13/2, off Intermediate Ring Road
Bengaluru - 560 071, India
Telephone: +91 80 4682 3000
Fax: +91 80 4682 3999

Limited Review Report on unaudited standalone financial results of HealthCare Global Enterprises Limited for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of HealthCare Global Enterprises Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of HealthCare Global Enterprises Limited (hereinafter referred to as "the Company") for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 ("the Statement").

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Vikash Gupta
Partner
Membership No.: 064597
UDIN:26064597RPUTWH1754

Bangalore
05 November 2026

HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489
Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED AND SIX MONTHS ENDED 30 SEPTEMBER 2026

(Rs. in Lakhs except share data)

Sl. No.	Particulars	Quarter ended 30 September 2026	Preceding quarter ended 30 June 2026	Corresponding quarter ended 30 September 2025	Six months ended 30 September 2026	Six months ended 30 September 2025	Previous year ended 31 March 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Income**						
	(a) Revenue from operations	39,604	37,525	34,441	77,129	67,034	135,937
	(b) Income from government grant	136	141	143	277	259	593
	(c) Other income	395	956	382	1,351	1,176	2,967
	Total income	**40,135**	**38,622**	**34,966**	**78,757**	**68,469**	**139,497**
2	**Expenses**						
	(a) Purchases of medical and non-medical items	9,611	9,561	9,077	19,172	17,501	35,864
	(b) Changes in inventories	333	(360)	(140)	(27)	(501)	(548)
	(c) Employee benefits expense	7,007	5,967	5,286	12,974	10,927	21,192
	(d) Finance costs	2,225	2,173	2,136	4,398	4,566	8,646
	(e) Depreciation and amortisation expense	3,574	3,957	3,016	7,531	5,841	11,980
	(f) Medical consultancy charges	8,083	7,734	6,563	15,817	12,991	26,343
	(g) Other expenses	8,934	8,842	7,568	17,776	15,160	29,520
	Total expenses	**39,767**	**37,874**	**33,506**	**77,641**	**66,485**	**132,997**
3	**Profit before exceptional items and tax (1-2)**	**368**	**748**	**1,460**	**1,116**	**1,984**	**6,500**
4	**Exceptional items (refer note 2)**	(661)	-	-	(661)	-	(5,538)
5	**Profit /(loss) before tax (3+4)**	**(293)**	**748**	**1,460**	**455**	**1,984**	**962**
6	**Tax expense**						
	- Current tax (refer note 6)	27	362	438	389	772	404
	- Deferred tax	(116)	(172)	(56)	(288)	(211)	(900)
	Total tax expense	**(89)**	**190**	**382**	**101**	**561**	**(496)**
7	**Profit / (loss) for the period /year (5-6)**	**(204)**	**558**	**1,078**	**354**	**1,423**	**1,458**
8	**Other comprehensive income / (loss)**						
	Items that will not be reclassified subsequently to profit or loss						
	- Remeasurements of the defined benefit plans	(83)	-	(15)	(83)	(15)	11
	- Income tax effect on above	21	-	4	21	4	(3)
	Other comprehensive income/ (loss) for the period / year, net of tax	**(62)**	**-**	**(11)**	**(62)**	**(11)**	**8**
9	**Total comprehensive income (loss) for the period / year (7+8)**	**(266)**	**558**	**1,067**	**292**	**1,412**	**1,466**
10	Paid-up equity share capital (Face value of Rs. 10 each)	14,930	14,930	14,100	14,930	14,100	14,930
11	Reserves, i.e., 'Other equity'						145,548
12	**Earnings/(loss) per equity share (face value of Rs. 10 each)**	Not annualised	Not annualised	Not annualised	Not annualised	Not annualised	Annualised
	(a) Basic (Rs.) (refer note 3)	(0.14)	0.37	0.77	0.24	1.01	1.03
	(b) Diluted (Rs.) (refer note 3)	(0.14)	0.37	0.76	0.24	1.00	1.03
	See accompanying notes to the Standalone Financial Results						

X Manish

HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489
Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED AND SIX MONTHS ENDED 30 SEPTEMBER 2026

STANDALONE BALANCE SHEET **(Rs. in Lakhs)**

	Particulars	As at 30 September 2026 Unaudited	As at 31 March 2026 Audited
A	**ASSETS**		
I	**Non-current assets**		
	(a) Property, plant and equipment	74,171	69,443
	(b) Capital work in progress	1,980	1,379
	(c) Right-of-use assets	39,021	33,078
	(d) Goodwill	9,014	9,014
	(e) Other intangible assets	560	688
	(f) Financial assets		
	(i) Investments (refer notes 2 and 4)	96,909	70,370
	(ii) Loans	-	201
	(ii) Other financial assets	9,446	8,564
	(g) Deferred tax assets (net)	689	381
	(g) Other tax assets (net)	7,528	6,913
	(h) Other non-current assets	5,642	3,539
	Total non current assets	**244,960**	**203,570**
II	**Current assets**		
	(a) Inventories	2,551	2,524
	(b) Financial assets		
	(i) Trade receivables	29,950	26,215
	(ii) Cash and cash equivalents	3,167	47,411
	(iii) Loans	117	156
	(iv) Other financial assets	4,380	6,121
	(c) Other current assets	7,435	2,510
		47,600	**84,937**
	Investments classified as held for sale (refer note 2 (ii))	-	3,227
	Total current assets	**47,600**	**88,164**
	Total assets	**292,560**	**291,734**
B	**EQUITY AND LIABILITIES**		
I	**Equity**		
	(a) Equity share capital	14,930	14,930
	(b) Other equity	146,137	145,548
	Total equity	**161,067**	**160,478**
II	**Liabilities**		
1	**Non-current liabilities**		
	(a) Financials liabilities		
	(i) Borrowings	28,639	31,506
	(ii) Lease liabilities	47,003	40,848
	(iii) Other financial liabilities	695	904
	(b) Provisions	555	1,632
	(c) Other non-current liabilities	3,900	3,325
	Total non - current liabilities	**80,792**	**78,215**
2	**Current liabilities**		
	(a) Financials liabilities		
	(i) Borrowings	20,634	25,199
	(ii) Lease liabilities	3,391	4,640
	(iii) Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	364	421
	Total outstanding dues of creditors other than micro enterprises and small enterprises	17,368	15,801
	(iv) Other financial liabilities	5,015	2,730
	(b) Other current liabilities	2,293	2,290
	(c) Provisions	1,387	1,711
	(d) Current tax liabilities (net)	249	249
	Total current liabilities	**50,701**	**53,041**
	Total equity and liabilities	**292,560**	**291,734**

See accompanying notes to the Standalone Financial Results

K Manish

HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489
Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED AND SIX MONTHS ENDED 30 SEPTEMBER 2026

Standalone Cash Flow Statement (Rs. in Lakhs)

Particulars	For the Six months ended 30 September 2026 Unaudited	For the Six months ended 30 September 2025 Unaudited
Cash flows from operating activities		
Profit / (loss) before tax	**455**	**1,984**
Adjustments for:		
Finance costs	4,398	4,566
Gain on investment revalued at FVTPL	(9)	(10)
Net gain on termination of lease	(86)	-
Guarantee commission income	(19)	(34)
Fair value change of financial liability	(218)	280
Finance lease income	(190)	(202)
Gain on disposal of property, plant and equipment	27	-
Loss allowance on trade receivables	922	589
Expenses on employee stock option scheme	298	120
ESOP Cash Settlement	-	(5,808)
Interest income	(229)	(842)
Income from government grant	(277)	(259)
Depreciation and amortisation expense	7,531	5,841
Payables no longer required written-back	(499)	-
Net foreign exchange (gain)	(30)	(21)
Provision for contingency (Refer note 2(i))	661	-
Movements in working capital:		
Changes in trade receivables	(4,627)	(2,174)
Changes in inventories	(27)	(501)
Changes in loans, financial assets and other assets	(3,500)	(3,031)
Changes in trade payables, financial liabilities and other liabilities	1,298	4,326
Changes in provisions	(1,483)	(39)
Cash generated from operations	**4,396**	**4,785**
Income taxes paid (net of refunds)	(838)	1,730
Net cash generated from operating activities (A)	**3,558**	**6,515**
Cash flows from investing activities		
Fixed deposits invested	(18,289)	(19)
Proceeds from maturity of fixed deposits	17,988	10,009
Acquisition of property, plant and equipment and others	(9,856)	(7,431)
Proceeds from disposal of property, plant and equipment	279	139
Interest received	92	-
Investment in subsidiaries	(26,531)	-
Proceeds from sale of investment in subsidiary	2,823	-
Proceeds from repayments of related party loans	201	-
Proceeds from sub-lease receivable	312	312
Net cash (used) in investing activities (B)	**(32,981)**	**3,010**
Cash flows from financing activities		
Proceeds from issue of equity shares	-	2,403
Proceeds from long-term borrowings	8,838	5,138
Repayment of long-term borrowings	(10,498)	(4,712)
Repayment of principal portion of lease liability	(2,760)	(1,863)
Interest paid on lease liability	(2,066)	(2,237)
Interest and other borrowing cost paid	(2,008)	(2,572)
Net cash generated from / (used in) financing activities (C)	**(8,494)**	**(3,843)**
Net increase/(decrease) in cash and cash equivalents (A+B+C)	**(37,917)**	**5,682**
Cash and cash equivalents at the beginning of the period	29,883	(12,175)
Cash and cash equivalents at the end of the period	**(8,034)**	**(6,493)**

Break up of cash and cash equivalents at the end of the period	For the Six months ended 30 September 2026	For the Six months ended 30 September 2025
Cash and cash equivalents at the end of the period (before adjustment of bank overdraft)	3,167	11,023
Less: Bank overdrafts repayable on demand	(11,201)	(17,516)
Cash and cash equivalents at the end of the period	**(8,034)**	**(6,493)**

K Manish

HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489
Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED AND SIX MONTHS ENDED 30 SEPTEMBER 2026

Notes:

1 This statement of standalone financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company') for the quarter and six months ended 30 September 2026 has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 05 November 2026. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

The Statement has been subjected to limited review by the statutory auditor of the Company. The review report of the statutory auditor is unqualified.

2 **Exceptional items:**

(i) The Company has availed customs duty exemptions on imported capital goods under the Export Promotion Capital Goods (EPCG) scheme, which are subject to the fulfillment of specified export obligations. During the quarter ended 30 September 2026, the Company evaluated the likelihood of meeting these export obligations and estimated a shortfall. Consequently, a provision of Rs. 661 lakhs has been recognized towards the estimated customs duty liability and applicable interest thereon.

(ii) During the previous year ended 31 March 2026, the management committed to a plan to divest the Company's entire equity interest in BACC Healthcare Private Limited ("BACC"), a wholly owned subsidiary engaged in the management of infertility treatment hospitals. Pursuant to the investor outreach process, non-binding offers were received from potential investors. Accordingly, the Company's investment in BACC, which was previously carried at cost less provision for diminution in value of investment, was reclassified as an "Investments classified as held for sale". Consequently, the investment was measured at the lower of its carrying amount and fair value less costs to sell. Accordingly, an impairment loss of Rs. 3,752 lakhs was recognised as an exceptional item during the previous year ended 31 March 2026 based on the fair value of the consideration receivable, net of related expenses.

During the preceding quarter, based on the recommendation of the Audit Committee, and pursuant to the approval of the Board of Directors at its meeting held on 19 May 2026, the Company completed the divestment of its entire equity interest in BACC to Inviga Healthcare Fund I and its nominee, a related party, for a consideration of Rs. 3,764 lakhs on 29 June 2026. Of the said consideration, Rs. 2,823 lakhs has been received upfront and the balance Rs. 941 lakhs is receivable within 18 months from the date of sale. Consequent to completion of the transaction, BACC ceased to be a subsidiary of the Company with effect from 30 June 2026.

(iii) During the previous year ended 31 March 2026, the recoverable amount of the Company's investment in HCG Kolkata Cancer Care LLP (formerly HCG EKO Oncology LLP), a wholly-owned subsidiary, was estimated to be lower than its carrying value, resulting in an impairment of Rs. 3,000 lakhs. As at 31 March 2026, the Company carried total investment of Rs. 13,157 lakhs in HCG Kolkata Cancer Care LLP, against which the cumulative provision for impairment is Rs. 6,120 lakhs. During the same period, based on a sustained improvement in operating performance of HCG Manavata Oncology LLP, a subsidiary, the conditions that had led to an impairment in earlier years no longer exist and accordingly an impairment reversal of Rs. 2,000 lakhs was recognised. As at 31 March 2026, the Company's aggregate investment in HCG Manavata Oncology LLP amounts to Rs. 5,715 lakhs.

(iv) During the previous year ended 31 March 2026, pursuant to the notification of new Labour Codes by the Government of India on 21 November 2025 resulting in change in wage definition, the incremental impact on the gratuity of Rs 640 lakhs and compensated absences of Rs 146 lakhs was recognised as an exceptional item, consistent with the guidance provided by the Institute of Chartered Accountants of India.

3 During the previous year ended 31 March 2026, the Company had completed a rights issue of 8,294,566 fully paid up equity shares of face value Rs. 10 each at an issue price of Rs. 512 per equity share (including a securities premium of Rs. 502 per equity share), aggregating to Rs. 42,468 lakhs. Share issue expenses amounting to Rs. 483 lakhs was adjusted against the securities premium reserve as per the applicable Ind AS and regulations. During the preceding quarter ended 30 June 2026, the entire issue proceeds were fully utilised for the objects specified in the Letter of Offer.

Earnings per share for the corresponding quarter and six months ended 30 September 2025 has been retrospectively adjusted for the bonus element in respect of Rights issue.

4 Pursuant to the Share Purchase Agreement (the "Agreement") dated 28 June 2024 with Vizag Hospital And Cancer Research Centre Private Limited ("VHCRPL") and its shareholders, the Company had acquired 51% equity shares of VHCRPL on 1 October 2024 for a consideration of Rs. 20,632 lakhs and acquired control of VHCRPL with effect from 2 October 2024. Further, as per the terms of the Agreement, the Company had committed to acquire an additional 34% of the equity share capital of VHCRPL for a consideration of Rs. 15,450 lakhs which was payable within 18 months from the date of first closing (i.e., 1 October 2024). The consideration for the balance 15% of the equity share capital will be determined as per the terms of the shareholders' agreement.

During the preceding quarter, on 13 April 2026, the Company completed the acquisition of the said additional 34% equity share capital of VHCRPL for an aggregate purchase consideration of Rs. 15,450 lakhs.

5 During the previous year ended 31 March 2026, the Board of Directors had approved the introduction and adoption of the HCG Employee Stock Option Scheme – 2026 ("HCG ESOS 2026"), under which the maximum number of options that can be granted is 74,21,455. During the current quarter, the shareholders of the Company have, by way of special resolutions passed through postal ballot on 8 July 2026, approved (i) the introduction and adoption of HCG ESOS 2026 to eligible employees and (ii) the grant of up to 18,55,364 options (representing 1.24% of the diluted equity share capital) under HCG ESOS 2026 to Dr. Manish Mattoo, Executive Director and Chief Executive Officer of the Company, in one or more tranches.

Pursuant to the approval of the Nomination and Remuneration Committee at its meeting held on 9 September 2026, the Company granted 64,46,843 Employee Stock Options to eligible employees (including Dr. Manish Mattoo, Executive Director and Chief Executive Officer) of the Company and its subsidiaries under HCG ESOS 2026.

6 The income tax expenses for the previous year ended 31 March 2026, is net of Rs. 1,820 lakhs relating to reversal of income taxes with respect to earlier years.

7 The Company has a single operating segment viz - 'setting up and managing hospitals and medical diagnostic services'.

For and on behalf of the Board of Directors

Dr. Manish Mattoo
Executive Director And Chief Executive Officer

HealthCare Global Enterprises Ltd.

Ahmedabad, 05 November 2026

B S R & Co. LLP
Chartered Accountants

Embassy Golf Links Business Park
Pebble Beach, B Block, 3rd Floor
No. 13/2, off Intermediate Ring Road
Bengaluru - 560 071, India
Telephone: +91 80 4682 3000
Fax: +91 80 4682 3999

Limited Review Report on unaudited consolidated financial results of HealthCare Global Enterprises Limited for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of HealthCare Global Enterprises Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of HealthCare Global Enterprises Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income of its joint venture for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I of this limited review report.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

VY.

6. We did not review the interim financial information of 11 Subsidiaries and 6 step down subsidiaries included in the Statement, whose interim financial information reflect total assets (before consolidation adjustments) of Rs. 91,248 lakhs as at 30 september 2026 and total revenues (before consolidation adjustments) of Rs. 17,205 lakhs and Rs. 32,198 lakhs, total net profit after tax (before consolidation adjustments) of Rs. 698 lakhs and Rs. 1,220 lakhs and total comprehensive income (before consolidation adjustments) of Rs. 855 lakhs and Rs. 1,426 lakhs, for the quarter ended 30 September 2026 and for the period from 1 April 2026 to 30 September 2026 respectively, and cash flows (net) (before consolidation adjustments) of Rs. 1,229 lakhs for the period from 1 April 2026 to 30 September 2026 as considered in the Statement. The Statement also include the Group's share of net profit after tax of Rs. 100 lakhs and Rs. 193 lakhs and total comprehensive income of Rs. 100 lakhs and Rs. 193 lakhs, for the quarter ended 30 September 2026 and for the period from 1 April 2026 to 30 September 2026 respectively as considered in the Statement, in respect of a joint venture, whose interim financial information has not been reviewed by us. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and a joint venture, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Vikash Gupta

Partner

Membership No.: 064597

UDIN:26064597VOMVEK4298

Bangalore

05 November 2026

Annexure I

List of entities (including step-down subsidiaries) and joint ventures in unaudited consolidated financial results.

Sr. No.	Name of the components	Relationship	Country of incorporation
1	BACC Healthcare Private Limited	Subsidiary (Till 29 June 2026)	India
2	HCG Medi-Surge Hospitals Private Limited	Subsidiary	India
3	HCG Oncology LLP	Subsidiary	India
4	HCG Oncology Hospitals LLP (formerly known as Apex HCG Oncology Hospitals LLP)	Subsidiary	India
5	HCG Manavata Oncology LLP	Subsidiary	India
6	Malnad Hospital & Institute of Oncology Private Limited	Subsidiary	India
7	HealthCare Diwan Chand Imaging LLP	Subsidiary	India
8	HCG NCHRI Oncology LLP	Subsidiary	India
9	Nagpur Cancer Hospital & Research Institute Private Limited	Subsidiary	India
10	HCG Kolkata Cancer Care LLP (formerly known as HCG EKO Oncology LLP)	Subsidiary	India
11	HCG Rajkot Hospitals LLP (formerly known as HCG Sun Hospitals LLP)	Subsidiary	India
12	Niruja Product Development & Healthcare Research Private Limited	Subsidiary	India
13	HealthCare Global Senthil Multi Specialty Private Limited	Subsidiary	India
14	Suchirayu Health Care Solutions Limited	Subsidiary	India
15	HCG (Mauritius) Pvt. Ltd.	Subsidiary	Mauritius

Sr. No.	Name of the components	Relationship	Country of incorporation
16	Vizag Hospital & Cancer Research Centre Private Limited	Subsidiary	India
17	HealthCare Global (Africa) Private Limited	Step-down subsidiary	Mauritius
18	Healthcare Global (Uganda) Private Limited	Step-down subsidiary	Uganda
19	Healthcare Global (Kenya) Private Limited	Step-down subsidiary	Kenya
20	Cancer Care Kenya Limited	Step-down subsidiary	Kenya
21	Vizag Hospital & Cancer Research Centre (Jharsuguda) Private Limited	Step-down subsidiary	India
22	Vizag Hospital & Cancer Research Centre (Odisha) Private Limited	Step-down subsidiary	India
23	Advanced Molecular Imaging Limited	Joint Venture	Kenya

HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489
Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED AND SIX MONTHS ENDED 30 SEPTEMBER 2026

(Rs. in Lakhs except share data)

Sl. No.	Particulars	Quarter ended 30 September 2026	Preceding quarter ended 30 June 2026	Corresponding quarter ended 30 September 2025	Six months ended 30 September 2026	Six months ended 30 September 2025	Previous year ended 31 March 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Income**						
	(a) Revenue from operations	73,016	69,339	64,516	142,355	125,696	253,843
	(b) Income from government grant	164	171	169	335	305	698
	(c) Other income (refer notes 2 and 4 (b))	191	1,213	262	1,404	945	2,499
	Total income	**73,371**	**70,723**	**64,947**	**144,094**	**126,946**	**257,040**
2	**Expenses**						
	(a) Purchases of medical and non-medical items	19,022	18,684	18,122	37,706	34,755	70,168
	(b) Changes in inventories	397	(804)	(407)	(407)	(853)	(938)
	(c) Employee benefits expense	11,448	10,452	9,418	21,900	19,195	37,860
	(d) Finance costs	3,842	3,987	4,362	7,829	8,909	17,657
	(e) Depreciation and amortisation expense	6,780	7,042	6,280	13,822	12,071	24,417
	(f) Medical consultancy charges	16,074	15,747	13,660	31,821	26,962	54,907
	(g) Other expenses	12,900	13,205	11,561	26,105	22,832	45,965
	Total expenses	**70,463**	**68,313**	**62,996**	**138,776**	**123,871**	**250,036**
3	**Profit before share of profit/(loss) of joint venture, exceptional items and tax (1-2)**	**2,908**	**2,410**	**1,951**	**5,318**	**3,075**	**7,004**
4	Share of profit / (loss) of joint venture	100	93	31	193	99	146
5	**Profit before exceptional items and tax (3+4)**	**3,008**	**2,503**	**1,982**	**5,511**	**3,174**	**7,150**
6	**Exceptional item (refer note 2)**	(1,159)	-	-	(1,159)	-	(4,458)
7	**Profit /(loss) before tax (5+6)**	**1,849**	**2,503**	**1,982**	**4,352**	**3,174**	**2,692**
8	**Tax expense**						
	- Current tax (refer note 5)	665	870	805	1,535	1,696	1,976
	- Deferred tax (refer note 5)	259	(13)	(889)	246	(1,186)	(1,562)
	Total tax expense/(credit)	**924**	**857**	**(84)**	**1,781**	**510**	**414**
9	**Profit / (loss) for the period / year (7-8)**	**925**	**1,646**	**2,066**	**2,571**	**2,664**	**2,278**
10	**Other comprehensive income/ (loss)**						
	(i) Items that will not be reclassified subsequently to profit or loss						
	- Remeasurements of the defined benefit plans	(38)	-	11	(38)	11	97
	- Income tax effect on above	10	-	(5)	10	(5)	(24)
	(ii) Items that will be reclassified to profit or loss						
	- Exchange differences on translation of financial statements of foreign operations	120	49	51	169	76	382
	Other comprehensive income for the period / year, net of tax	**92**	**49**	**57**	**141**	**82**	**455**
11	**Total comprehensive income / (loss) for the period / year (9+10)**	**1,017**	**1,695**	**2,123**	**2,712**	**2,746**	**2,733**
	Profit for the period / year attributable to:						
	Owners of the Company	479	1,377	1,627	1,856	2,102	1,376
	Non-controlling interests	446	269	439	715	562	902
	Other comprehensive income / (loss) for the period / year attributable to						
	Owners of the Company	67	47	78	114	95	455
	Non-controlling interests	25	2	(21)	27	(13)	-
	Total comprehensive income for the period / year attributable to						
	Owners of the Company	546	1,424	1,705	1,970	2,197	1,831
	Non-controlling interests	471	271	418	742	549	902
12	Paid-up equity share capital (Face value of Rs. 10 each)	14,930	14,930	14,100	14,930	14,100	14,930
13	Reserves, i.e., 'Other equity'						118,267
14	**Earnings / (loss) per equity share (face value of Rs. 10 each)**	Not annualised	Not annualised	Not annualised	Not annualised	Not annualised	Annualised
	(a) Basic (Rs.) (refer note 3)	0.32	0.92	1.15	1.24	1.49	0.97
	(b) Diluted (Rs.) (refer note 3)	0.32	0.92	1.15	1.24	1.48	0.96

See accompanying notes to the Consolidated Financial Results

HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489
Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED AND SIX MONTHS ENDED 30 SEPTEMBER 2026

Consolidated Cash Flow Statement **(Rs. in Lakhs)**

Particulars	For the Six months ended 30 September 2026	For the Six months ended 30 September 2025
	Unaudited	Unaudited
Cash flows from operating activities		
Profit before tax	4,352	3,174
Adjustments for:		
Finance costs	7,829	8,909
Gain on investment revalued at FVTPL	(9)	(10)
Loss on disposal of property, plant and equipment	33	3
Loss allowance on trade receivables	878	625
Expenses on employee stock option scheme	298	143
ESOP Cash Settlement	-	(5,808)
Interest income	(362)	(783)
Net gain on termination of lease	(86)	-
Payables no longer required written-back	(499)	-
Depreciation and amortisation expense	13,822	12,071
Income from government grant	(335)	(305)
Net foreign exchange (gain)	(35)	(16)
Share of (profit) / loss of equity accounted investee	(193)	(99)
Provision for contingency (Refer note 2(i))	1,159	-
Gain on disposal of subsidiary (Refer note 2(ii))	(296)	-
Movements in working capital:		
Changes in trade receivables	(7,449)	(3,708)
Changes in inventories	(407)	(853)
Changes in loans, financial assets and other assets	(5,864)	(2,343)
Changes in trade payables, financial liabilities and other liabilities	6,493	9,442
Changes in provisions	(1,330)	(12)
Cash generated from operations	**17,999**	**20,430**
Income taxes paid (net of refunds)	(4,070)	(1,205)
Net cash generated from operating activities (A)	**13,929**	**19,225**
Cash flows from investing activities		
Fixed deposits invested	(19,115)	(1,652)
Proceeds from maturity of fixed deposits	18,042	11,143
Acquisition of property, plant and equipment and others	(13,049)	(15,832)
Proceeds from disposal of property, plant and equipment	261	231
Payment towards settlement of put option exercised by the non-controlling interest in subsidiary	(15,450)	-
Interest received	146	310
Invesment in others	(38)	-
Proceeds from disposal of subsidiary (net of cash and cash equivalents) (Refer note 2(ii))	2,234	-
Net cash (used) in investing activities (B)	**(26,969)**	**(5,800)**
Cash flows from financing activities		
Proceeds from issue of equity shares	-	2,403
Proceeds from long-term borrowings	11,187	7,436
Repayment of long-term borrowings	(22,683)	(6,779)
Repayment of principle portion of lease liability	(3,788)	(2,572)
Interest paid on lease liability	(3,997)	(4,218)
Interest and other borrowing cost paid	(3,185)	(4,335)
Net cash generated / (used) in financing activities (C)	**(22,466)**	**(8,065)**
Net increase/(decrease) in cash and cash equivalents (A+B+C)	**(35,506)**	**5,360**
Cash and cash equivalents at the beginning of the period	36,323	(4,707)
Cash and cash equivalents at the end of the period	**817**	**653**

Break up of cash and cash equivalents at the end of the period	For the Six months ended 30 September 2026	For the Six months ended 30 September 2025
Cash and cash equivalents at the end of the period as per Balance Sheet (before adjustment of bank overdraft)	12,018	18,261
Less: Bank overdrafts repayable on demand	(11,201)	(17,608)
Cash and cash equivalents at the end of the period	**817**	**653**

X Manish

HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489
Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED AND SIX MONTHS ENDED 30 SEPTEMBER 2026

CONSOLIDATED BALANCE SHEET **(Rs. in Lakhs)**

	Particulars	As at 30 September 2026 Unaudited	As at 31 March 2026 Audited
A	**ASSETS**		
I	**Non-current assets**		
	(a) Property, plant and equipment	147,394	139,279
	(b) Capital work in progress	2,430	1,856
	(c) Right-of-use assets	69,167	64,836
	(d) Goodwill	38,761	38,759
	(e) Other intangible assets	2,647	3,287
	(f) Investment in equity accounted investee	894	682
	(g) Financial assets		
	(i) Investments	753	707
	(ii) Other financial assets	8,437	8,239
	(h) Deferred tax assets (net)	3,843	3,992
	(i) Other tax assets (net)	13,456	10,742
	(j) Other non-current assets	5,743	6,354
	Total non current assets	**293,525**	**278,733**
II	**Current assets**		
	(a) Inventories	6,364	5,982
	(b) Financial assets		
	(i) Trade receivables	48,573	42,070
	(ii) Cash and cash equivalents	12,018	53,605
	(iii) Bank balance other than cash and cash equivalents above	719	487
	(iv) Loans	289	336
	(v) Other financial assets	3,072	1,129
	(c) Other current assets	8,426	3,241
		79,461	**106,850**
	Assets included in disposal group held for sale (refer note 2(ii))	-	6,671
	Total current assets	**79,461**	**113,521**
	Total assets	**372,986**	**392,254**
B	**EQUITY AND LIABILITIES**		
I	**Equity**		
	(a) Equity share capital	14,930	14,930
	(b) Other equity	119,927	118,267
	Equity attributable to equity holders of the Company	**134,857**	**133,197**
	Non- controlling interests	8,565	7,824
	Total equity	**143,422**	**141,021**
II	**Liabilities**		
1	**Non-current liabilities**		
	(a) Financials Liabilities		
	(i) Borrowings	46,862	59,919
	(ii) Lease liabilities	81,426	75,998
	(iii) Other financial liabilities	7,603	6,995
	(b) Provisions	1,537	2,526
	(c) Deferred tax liabilities (net)	314	234
	(d) Other non-current liabilities	4,775	3,845
	Total non-current liabilities	**142,517**	**149,517**
2	**Current liabilities**		
	(a) Financials liabilities		
	(i) Borrowings	27,375	31,122
	(ii) Lease liabilities	5,265	6,497
	(iii) Trade payables		
	Total outstanding dues of micro enterprises and small	787	559
	Total outstanding dues of creditors other than micro	39,558	34,545
	(iv) Other financial liabilities	6,909	18,967
	(b) Other current liabilities	4,674	3,884
	(c) Provisions	2,126	2,338
	(d) Current tax liabilities (net)	353	360
		87,047	**98,272**
	Liabilities included in disposal group held for sale (refer note 2(ii))	-	3,444
	Total current liabilities	**87,047**	**101,716**
	Total equity and liabilities	**372,986**	**392,254**

See accompanying notes to the Consolidated Financial Results

HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489
Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED AND SIX MONTHS ENDED 30 SEPTEMBER 2026

Notes to conoslidated financial results:

1 This statement of consolidated financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company'), and its subsidiaries (collectively referred to as "the Group") and its joint venture for the quarter and six months period ended 30 September 2026 has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 05 November 2026. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

The Statement has been subjected to limited review by the statutory auditor of the Company. The review report of the statutory auditor is unmodified.

2 **Exceptional items:**

(i) The Group has availed customs duty exemptions on imported capital goods under the Export Promotion Capital Goods (EPCG) scheme, which are subject to the fulfillment of specified export obligations. During the quarter ended 30 September 2026, the Group evaluated the likelihood of meeting these export obligations and estimated a shortfall. Consequently, a provision of Rs. 1,159 lakhs has been recognized towards the estimated customs duty liability and applicable interest thereon.

(ii) During the previous year ended 31 March 2026, the management committed to a plan to divest the Company's entire equity interest in BACC Healthcare Private Limited ("BACC"), a wholly owned subsidiary engaged in the management of infertility treatment hospitals. Accordingly, the assets and liabilities of BACC were classified as a disposal group held for sale as at 31 March 2026. Along with the classification as held for sale, the carrying amount of goodwill allocated to the cash-generating unit (i.e., BACC) was assessed for impairment in accordance with Ind AS 36 and an impairment loss of Rs. 3,191 lakhs was recognised as an exceptional item during the previous year ended 31 March 2026 based on the fair value of the consideration receivable, net of related expenses.

During the preceding quarter ended 30 June 2026, based on the recommendation of the Audit Committee, and pursuant to the approval of the Board of Directors at its meeting held on 19 May 2026, the Company completed the divestment of its entire equity interest in BACC to Inviga Healthcare Fund I and its nominee, a related party, for a consideration of Rs. 3,764 lakhs on 29 June 2026 and recognised resulting gain of Rs. 296 lakhs in Other income. Of the said consideration, Rs. 2,823 lakhs has been received upfront and the balance Rs. 941 lakhs is receivable within 18 months from the date of sale. Consequent to completion of the transaction, BACC ceased to be a subsidiary of the Company with effect from 30 June 2026.

(iii) During the previous year ended 31 March 2026, pursuant to the notification of new Labour Codes by the Government of India on 21 November 2025 resulting in change in wage definition, the incremental impact on the employee benefit obligations aggregating Rs. 1,267 lakhs was recognised as an exceptional item, consistent with the guidance provided by the Institute of Chartered Accountants of India.

3 During the previous year ended 31 March 2026, the Company had completed a rights issue of 8,294,566 fully paid up equity shares of face value Rs. 10 each at an issue price of Rs. 512 per equity share (including a securities premium of Rs. 502 per equity share), aggregating to Rs. 42,468 lakhs. Share issue expenses amounting to Rs. 483 lakhs were adjusted against the securities premium reserve as per the applicable Ind AS and regulations. During the preceding quarter ended 30 June 2026, the entire issue proceeds were fully utilised for the objects specified in the Letter of Offer.

Earnings per share for the corresponding quarter and six months ended 30 September 2025 have been retrospectively adjusted for the bonus element in respect of the Rights issue.

4 (a) Pursuant to the Share Purchase Agreement (the "Agreement") dated 28 June 2024 with Vizag Hospital And Cancer Research Centre Private Limited ("VHCRPL") and its shareholders, the Company had acquired 51% equity shares of VHCRPL on 1 October 2024 for a consideration of Rs. 20,632 lakhs and acquired control of VHCRPL with effect from 2 October 2024. Further, as per the terms of the Agreement, the Company had committed to acquire an additional 34% of the equity share capital of VHCRPL for a consideration of Rs. 15,450 lakhs which was payable within 18 months from the date of first closing (i.e., 1 October 2024). The consideration for the balance 15% of the equity share capital will be determined as per the terms of the shareholders' agreement.

During the preceding quarter, on 13 April 2026, the Company completed the acquisition of the said additional 34% equity share capital of VHCRPL for an aggregate purchase consideration of Rs. 15,450 lakhs.

(b) During the previous year ended 31 March 2026, the Group had recognised a gain of Rs. 700 lakhs under the heading 'Other Income', in respect of trade receivables acquired through the business combination referred to above (accounted for under Ind AS 103 "Business Combinations"), on account of changes in the fair value (recoverability) of these receivables.

5 (a) The income tax expenses for the previous year ended 31 March 2026, is net of Rs. 1,820 lakhs relating to reversal of income taxes with respect to earlier years.

(b) During the previous year ended 31 March 2026, the management reassessed whether the Company's Subsidiary, HCG Oncology LLP would have sufficient taxable profits to utilize its unused tax losses in the foreseeable future considering the improvement in its performance and utilization of tax losses accumulated in the earlier years. Accordingly, based on the reasonable certainty of availability of future profits in the foreseeable future, the Group recognized a deferred tax asset/credit of Rs. 960 lakhs on the brought forward business losses and unabsorbed depreciation with respect to this subsidiary.

6 During the previous year ended 31 March 2026, the Board of Directors had approved the introduction and adoption of the HCG Employee Stock Option Scheme – 2026 ("HCG ESOS 2026"), under which the maximum number of options that can be granted is 74,21,455. During the current quarter, the shareholders of the Company have, by way of special resolutions passed through postal ballot on 8 July 2026, approved (i) the introduction and adoption of HCG ESOS 2026 to eligible employees and (ii) the grant of up to 18,55,364 options (representing 1.24% of the diluted equity share capital) under HCG ESOS 2026 to Dr. Manish Mattoo, Executive Director and Chief Executive Officer of the Company, in one or more tranches.

Pursuant to the approval of the Nomination and Remuneration Committee at its meeting held on 9 September 2026, the Company granted 64,46,843 Employee Stock Options to eligible employees (including Dr. Manish Mattoo, Executive Director and Chief Executive Officer) of the Company and its subsidiaries under HCG ESOS 2026.

7 The Group has a single operating segment viz. -'setting up and managing hospitals and medical diagnostic services'

8 Subsequent event: On 5 October 2026, Healthcare Global (Kenya) Private Limited (HCGKL), a step-down subsidiary of the Company, acquired additional 10 ordinary equity shares of Advanced Molecular Imaging Limited (AMIL), thereby increasing the ownership stake in AMIL from 50% to 50.10% and amended certain provisions of the original joint venture agreement dated 21st September 2017 whereby the power to make key operating and financial decisions shifts from the joint management committee to Board, wherein HCGKL has majority representation. Consequently, by virtue of having a majority shareholding and majority representation on the board of AMIL, AMIL will become a step-down subsidiary of the group and will be consolidated effective 5 October 2026.

For and on behalf of the Board of Directors

Dr. Manish Mattoo
Executive Director And Chief Executive Officer

Ahmedabad, 05 November 2026

HealthCare Global Enterprises Ltd.